Progressive Neurochemical Abnormalities in Cognitive and Motor Subgroups of Amyotrophic Lateral Sclerosis: A Prospective Multicenter Study.

Adult Aged Amyotrophic Lateral Sclerosis / complications Aspartic Acid / analogs & derivatives Cognitive Dysfunction / diagnostic imaging Disease Progression Female Humans Longitudinal Studies Magnetic Resonance Spectroscopy / methods Male Middle Aged Motor Cortex / diagnostic imaging Prefrontal Cortex / diagnostic imaging Severity of Illness Index

Journal

Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060

Informations de publication

Date de publication:
24 08 2021
Historique:
received: 13 01 2021
accepted: 19 05 2021
entrez: 24 8 2021
pubmed: 25 8 2021
medline: 4 9 2021
Statut: ppublish

Résumé

To evaluate progressive cerebral degeneration in amyotrophic lateral sclerosis (ALS) by assessing alterations in Seventy-six patients with ALS and 59 healthy controls were enrolled in a prospective, longitudinal, multicenter study in the Canadian ALS Neuroimaging Consortium. Participants underwent serial clinical evaluations and magnetic resonance spectroscopy at baseline and 4 and 8 months using a harmonized protocol across 5 centers. NAA ratios were quantified in the motor cortex and prefrontal cortex. Patients were stratified into subgroups based on disease progression rate, upper motor neuron (UMN) signs, and cognitive status. Linear mixed models were used for baseline and longitudinal comparisons of NAA metabolite ratios. Patients with ALS had reduced NAA ratios in the motor cortex at baseline ( Progressive degeneration of the motor cortex in ALS is associated with more aggressive clinical presentations. These findings provide biological evidence of variable spatial and temporal cerebral degeneration linked to the disease heterogeneity of ALS. The use of standardized imaging protocols may have a role in clinical trials for patient selection or subgrouping. This study provides Class II evidence that MRS NAA metabolite ratios of the motor cortex are associated with more rapid disease progression and greater UMN signs in patients with ALS. ClinicalTrials.gov Identifier: NCT02405182.

Identifiants

DOI: 10.1212/WNL.0000000000012367 PMID: 34426551 PMC: PMC8397589
pubmed: 34426551
pii: WNL.0000000000012367
doi: 10.1212/WNL.0000000000012367
pmc: PMC8397589
doi:

Substances chimiques

Aspartic Acid 30KYC7MIAI
N-acetylaspartate 997-55-7

Banques de données

ClinicalTrials.gov
['NCT02405182']

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e803-e813

Subventions

Organisme : CIHR
Pays : Canada

Informations de copyright

© 2021 American Academy of Neurology.

Références

J Neurol Sci. 2015 Jan 15;348(1-2):206-10
pubmed: 25524526
Arch Neurol. 2006 Aug;63(8):1144-8
pubmed: 16908742
Neurology. 2020 Jun 16;94(24):e2592-e2604
pubmed: 32414878
AJNR Am J Neuroradiol. 2011 Oct;32(9):1677-80
pubmed: 21778247
J Neurosci Rural Pract. 2016 Jan-Mar;7(1):102-8
pubmed: 26933355
Front Neurol. 2019 May 10;10:482
pubmed: 31133975
J Neurol Sci. 2001 Sep 15;190(1-2):21-7
pubmed: 11574102
Neuroradiology. 2001 Jul;43(7):537-41
pubmed: 11512581
PLoS One. 2012;7(8):e42816
pubmed: 22880116
Lancet Neurol. 2009 Jan;8(1):94-109
pubmed: 19081518
Neurology. 1999 Nov 10;53(8):1665-70
pubmed: 10563610
Amyotroph Lateral Scler. 2009 Oct-Dec;10(5-6):324-31
pubmed: 19922119
Amyotroph Lateral Scler Frontotemporal Degener. 2014 Mar;15(1-2):9-14
pubmed: 23781974
Amyotroph Lateral Scler. 2009 Jun;10(3):168-74
pubmed: 19058055
Neurology. 2004 May 25;62(10):1753-7
pubmed: 15159473
Neurol Res. 2009 Jun;31(5):472-7
pubmed: 19215666
Arch Neurol. 1998 Jul;55(7):931-6
pubmed: 9678310
J Neurol Sci. 1999 Oct 31;169(1-2):13-21
pubmed: 10540002
Neurology. 2012 Aug 7;79(6):583-8
pubmed: 22843269
Clin Investig (Lond). 2014;4(7):605-618
pubmed: 28203356
Radiology. 1999 Sep;212(3):763-9
pubmed: 10478245
Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Sep;5(3):141-9
pubmed: 15512902
Neurology. 2007 Apr 24;68(17):1402-10
pubmed: 17452585
J Neurol Neurosurg Psychiatry. 2006 Nov;77(11):1253-5
pubmed: 16835288
Neurol Clin Pract. 2019 Oct;9(5):400-407
pubmed: 31750025
Neurology. 2020 Aug 25;95(8):e943-e952
pubmed: 32646955
Neuroimage Clin. 2016 Oct 22;12:1035-1043
pubmed: 27995069
Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Dec;1(5):293-9
pubmed: 11464847
Curr Med Chem. 2007;14(30):3185-200
pubmed: 18220753
PLoS One. 2017 May 12;12(5):e0177680
pubmed: 28498852
AJNR Am J Neuroradiol. 2011 Feb;32(2):403-7
pubmed: 21087934
Amyotroph Lateral Scler. 2010;11(1-2):157-65
pubmed: 19242831
PLoS One. 2013 Nov 20;8(11):e80748
pubmed: 24278317
J Neurol Neurosurg Psychiatry. 2019 Mar;90(3):294-301
pubmed: 30467209
Amyotroph Lateral Scler Frontotemporal Degener. 2020 May;21(3-4):246-251
pubmed: 32067510
Front Psychol. 2012 Apr 17;3:111
pubmed: 22529829
Radiology. 2006 Jun;239(3):831-8
pubmed: 16641339
AJNR Am J Neuroradiol. 2014 Feb;35(2):304-10
pubmed: 24113470
AJNR Am J Neuroradiol. 2010 Nov;31(10):1799-806
pubmed: 20801763
J Neurol. 2007 Aug;254(8):1099-106
pubmed: 17431700
Neurology. 2002 Mar 12;58(5):773-9
pubmed: 11889242

Auteurs

Daniel Ta (D)

From the Neuroscience and Mental Health Institute (D.T., A.I., O.S., S.K.), Department of Biomedical Engineering (C.H., P.S.), School of Public Health (D.T.E.), and Division of Neurology (C.L., S.K.), University of Alberta, Edmonton; Division of Neurology (H.B.), University of British Columbia, Vancouver; Seaman Family MR Centre (R.F.) and Hotchkiss Brain Institute (R.F., L.K.), University of Calgary, Alberta; Montreal Neurological Institute (A.L.G.), McGill University, Quebec; and Sunnybrook Health Sciences Centre (S.J.G., L.Z.), University of Toronto, Ontario, Canada. sanjay.kalra@ualberta.ca.
ORCID: 0000-0002-4975-2970

Abdullah Ishaque (A)

From the Neuroscience and Mental Health Institute (D.T., A.I., O.S., S.K.), Department of Biomedical Engineering (C.H., P.S.), School of Public Health (D.T.E.), and Division of Neurology (C.L., S.K.), University of Alberta, Edmonton; Division of Neurology (H.B.), University of British Columbia, Vancouver; Seaman Family MR Centre (R.F.) and Hotchkiss Brain Institute (R.F., L.K.), University of Calgary, Alberta; Montreal Neurological Institute (A.L.G.), McGill University, Quebec; and Sunnybrook Health Sciences Centre (S.J.G., L.Z.), University of Toronto, Ontario, Canada.

Ojas Srivastava (O)

From the Neuroscience and Mental Health Institute (D.T., A.I., O.S., S.K.), Department of Biomedical Engineering (C.H., P.S.), School of Public Health (D.T.E.), and Division of Neurology (C.L., S.K.), University of Alberta, Edmonton; Division of Neurology (H.B.), University of British Columbia, Vancouver; Seaman Family MR Centre (R.F.) and Hotchkiss Brain Institute (R.F., L.K.), University of Calgary, Alberta; Montreal Neurological Institute (A.L.G.), McGill University, Quebec; and Sunnybrook Health Sciences Centre (S.J.G., L.Z.), University of Toronto, Ontario, Canada.

Chris Hanstock (C)

From the Neuroscience and Mental Health Institute (D.T., A.I., O.S., S.K.), Department of Biomedical Engineering (C.H., P.S.), School of Public Health (D.T.E.), and Division of Neurology (C.L., S.K.), University of Alberta, Edmonton; Division of Neurology (H.B.), University of British Columbia, Vancouver; Seaman Family MR Centre (R.F.) and Hotchkiss Brain Institute (R.F., L.K.), University of Calgary, Alberta; Montreal Neurological Institute (A.L.G.), McGill University, Quebec; and Sunnybrook Health Sciences Centre (S.J.G., L.Z.), University of Toronto, Ontario, Canada.

Peter Seres (P)

From the Neuroscience and Mental Health Institute (D.T., A.I., O.S., S.K.), Department of Biomedical Engineering (C.H., P.S.), School of Public Health (D.T.E.), and Division of Neurology (C.L., S.K.), University of Alberta, Edmonton; Division of Neurology (H.B.), University of British Columbia, Vancouver; Seaman Family MR Centre (R.F.) and Hotchkiss Brain Institute (R.F., L.K.), University of Calgary, Alberta; Montreal Neurological Institute (A.L.G.), McGill University, Quebec; and Sunnybrook Health Sciences Centre (S.J.G., L.Z.), University of Toronto, Ontario, Canada.

Dean T Eurich (DT)

From the Neuroscience and Mental Health Institute (D.T., A.I., O.S., S.K.), Department of Biomedical Engineering (C.H., P.S.), School of Public Health (D.T.E.), and Division of Neurology (C.L., S.K.), University of Alberta, Edmonton; Division of Neurology (H.B.), University of British Columbia, Vancouver; Seaman Family MR Centre (R.F.) and Hotchkiss Brain Institute (R.F., L.K.), University of Calgary, Alberta; Montreal Neurological Institute (A.L.G.), McGill University, Quebec; and Sunnybrook Health Sciences Centre (S.J.G., L.Z.), University of Toronto, Ontario, Canada.

Collin Luk (C)

From the Neuroscience and Mental Health Institute (D.T., A.I., O.S., S.K.), Department of Biomedical Engineering (C.H., P.S.), School of Public Health (D.T.E.), and Division of Neurology (C.L., S.K.), University of Alberta, Edmonton; Division of Neurology (H.B.), University of British Columbia, Vancouver; Seaman Family MR Centre (R.F.) and Hotchkiss Brain Institute (R.F., L.K.), University of Calgary, Alberta; Montreal Neurological Institute (A.L.G.), McGill University, Quebec; and Sunnybrook Health Sciences Centre (S.J.G., L.Z.), University of Toronto, Ontario, Canada.

Hannah Briemberg (H)

From the Neuroscience and Mental Health Institute (D.T., A.I., O.S., S.K.), Department of Biomedical Engineering (C.H., P.S.), School of Public Health (D.T.E.), and Division of Neurology (C.L., S.K.), University of Alberta, Edmonton; Division of Neurology (H.B.), University of British Columbia, Vancouver; Seaman Family MR Centre (R.F.) and Hotchkiss Brain Institute (R.F., L.K.), University of Calgary, Alberta; Montreal Neurological Institute (A.L.G.), McGill University, Quebec; and Sunnybrook Health Sciences Centre (S.J.G., L.Z.), University of Toronto, Ontario, Canada.

Richard Frayne (R)

From the Neuroscience and Mental Health Institute (D.T., A.I., O.S., S.K.), Department of Biomedical Engineering (C.H., P.S.), School of Public Health (D.T.E.), and Division of Neurology (C.L., S.K.), University of Alberta, Edmonton; Division of Neurology (H.B.), University of British Columbia, Vancouver; Seaman Family MR Centre (R.F.) and Hotchkiss Brain Institute (R.F., L.K.), University of Calgary, Alberta; Montreal Neurological Institute (A.L.G.), McGill University, Quebec; and Sunnybrook Health Sciences Centre (S.J.G., L.Z.), University of Toronto, Ontario, Canada.
ORCID: 0000-0003-0358-1210

Angela L Genge (AL)

From the Neuroscience and Mental Health Institute (D.T., A.I., O.S., S.K.), Department of Biomedical Engineering (C.H., P.S.), School of Public Health (D.T.E.), and Division of Neurology (C.L., S.K.), University of Alberta, Edmonton; Division of Neurology (H.B.), University of British Columbia, Vancouver; Seaman Family MR Centre (R.F.) and Hotchkiss Brain Institute (R.F., L.K.), University of Calgary, Alberta; Montreal Neurological Institute (A.L.G.), McGill University, Quebec; and Sunnybrook Health Sciences Centre (S.J.G., L.Z.), University of Toronto, Ontario, Canada.

Simon J Graham (SJ)

From the Neuroscience and Mental Health Institute (D.T., A.I., O.S., S.K.), Department of Biomedical Engineering (C.H., P.S.), School of Public Health (D.T.E.), and Division of Neurology (C.L., S.K.), University of Alberta, Edmonton; Division of Neurology (H.B.), University of British Columbia, Vancouver; Seaman Family MR Centre (R.F.) and Hotchkiss Brain Institute (R.F., L.K.), University of Calgary, Alberta; Montreal Neurological Institute (A.L.G.), McGill University, Quebec; and Sunnybrook Health Sciences Centre (S.J.G., L.Z.), University of Toronto, Ontario, Canada.

Lawrence Korngut (L)

From the Neuroscience and Mental Health Institute (D.T., A.I., O.S., S.K.), Department of Biomedical Engineering (C.H., P.S.), School of Public Health (D.T.E.), and Division of Neurology (C.L., S.K.), University of Alberta, Edmonton; Division of Neurology (H.B.), University of British Columbia, Vancouver; Seaman Family MR Centre (R.F.) and Hotchkiss Brain Institute (R.F., L.K.), University of Calgary, Alberta; Montreal Neurological Institute (A.L.G.), McGill University, Quebec; and Sunnybrook Health Sciences Centre (S.J.G., L.Z.), University of Toronto, Ontario, Canada.

Lorne Zinman (L)

From the Neuroscience and Mental Health Institute (D.T., A.I., O.S., S.K.), Department of Biomedical Engineering (C.H., P.S.), School of Public Health (D.T.E.), and Division of Neurology (C.L., S.K.), University of Alberta, Edmonton; Division of Neurology (H.B.), University of British Columbia, Vancouver; Seaman Family MR Centre (R.F.) and Hotchkiss Brain Institute (R.F., L.K.), University of Calgary, Alberta; Montreal Neurological Institute (A.L.G.), McGill University, Quebec; and Sunnybrook Health Sciences Centre (S.J.G., L.Z.), University of Toronto, Ontario, Canada.

Sanjay Kalra (S)

From the Neuroscience and Mental Health Institute (D.T., A.I., O.S., S.K.), Department of Biomedical Engineering (C.H., P.S.), School of Public Health (D.T.E.), and Division of Neurology (C.L., S.K.), University of Alberta, Edmonton; Division of Neurology (H.B.), University of British Columbia, Vancouver; Seaman Family MR Centre (R.F.) and Hotchkiss Brain Institute (R.F., L.K.), University of Calgary, Alberta; Montreal Neurological Institute (A.L.G.), McGill University, Quebec; and Sunnybrook Health Sciences Centre (S.J.G., L.Z.), University of Toronto, Ontario, Canada. sanjay.kalra@ualberta.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Progressive Neurochemical Abnormalities in...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Progressive Neurochemical Abnormalities in...
questionsmedicales.fr › Maladies métaboliques et nutritionnelles › Maladies métaboliques › Troubles de l'homéostasie des protéines › Protéinopathies TDP-43 › Sclérose latérale amyotrophique › Progressive Neurochemical Abnormalities in...
questionsmedicales.fr › Acides aminés, peptides et protéines › Acides aminés › Acides aminés excitateurs › Acide aspartique › Progressive Neurochemical Abnormalities in...
questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Troubles de la cognition › Dysfonctionnement cognitif › Progressive Neurochemical Abnormalities in...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Évolution de la maladie › Progressive Neurochemical Abnormalities in...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Progressive Neurochemical Abnormalities in...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études longitudinales › Progressive Neurochemical Abnormalities in...
questionsmedicales.fr › Techniques d'investigation › Techniques de chimie analytique › Analyse spectrale › Spectroscopie par résonance magnétique › Progressive Neurochemical Abnormalities in...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Progressive Neurochemical Abnormalities in...
questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › Prosencéphale › Télencéphale › Cerveau › Cortex cérébral › Cortex sensorimoteur › Cortex moteur › Progressive Neurochemical Abnormalities in...
questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › Prosencéphale › Télencéphale › Cerveau › Cortex cérébral › Lobe frontal › Cortex préfrontal › Progressive Neurochemical Abnormalities in...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Enquêtes et questionnaires › Enquêtes de santé › Indicateurs d'état de santé › Acuité des besoins du patient › Indice de gravité de la maladie › Progressive Neurochemical Abnormalities in...